• 1
    Brennan MF, Singer S, Maki RG, O'Sullivan B. Soft tissue sarcoma. In: DeVitaVT, HellmannS, RosenbergSA, eds. Cancer Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 1741-1794.
  • 2
    Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008; 97: 314-320.
  • 3
    Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002.
  • 4
    Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998; 338: 153-160.
  • 5
    Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001; 31: 362-372.
  • 6
    Singer S, Baldini EH, Demetri GD, et al. Synovial sarcoma: prognostic significance of tumor size, margin of resection and mitotic activity for survival. J Clin Oncol. 1996; 14: 1201-1208.
  • 7
    Lewis JJ, Antonescu CR, Leung DHY, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18: 2087-2094.
  • 8
    Spillane AJ, A'Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000; 18: 3794-3803.
  • 9
    Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001; 19: 525-534.
  • 10
    Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004; 22: 4040-4050.
  • 11
    Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004; 101: 627-634.
  • 12
    Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002; 62: 135-140.
  • 13
    Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer. 1994; 73: 2506-2511.
  • 14
    Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 112: 1585-1591.
  • 15
    Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105-113.
  • 16
    Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000; 4: 151-160.
  • 17
    Gortzak E, Azzarelli A, Buesa J, et al. A randomized phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001; 37: 1096-1103.
  • 18
    Frustaci S, Gherlinzoni F, DePaoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcoma of the extremity and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
  • 19
    Pisters PW, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007; 25: 1003-1008.
  • 20
    Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg. 1980; 62-A: 1027-1030.
  • 21
    Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 2002; 95: 843-851.
  • 22
    Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003; 21: 1602-1611.
  • 23
    Spurrell EL, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005; 16: 437-444.
  • 24
    Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituti Ortopedici Rizzoli. J Clin Oncol. 2000; 18: 4-11.
  • 25
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 3108-3114.
  • 26
    Lewis JJ, Leung D, Heslin M, et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997; 15: 646-652.
  • 27
    Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003; 237: 218-226.
  • 28
    Casali PG, Jost L, Sleijfer S, et al. ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations. Ann Oncol. 2008; 19( suppl 2): ii89-ii93.
  • 29
    Kampe CE, Rosen G, Eilber F, et al. A study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993; 72: 2161-2169.
  • 30
    Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007; 96: 118-123.
  • 31
    van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996; 77: 675-682.